Early Access — free while we kick the tires
EdgarHawk

GARCIA RUBEN A

General Counsel

Officer
2 filings analyzed · 1 company · Latest 2026-03-02

Companies

Company Buys Sells Direction
FibroBiologics, Inc. FBLG 2 0 Net buying

Activity

March 2026
2026-03-02 FibroBiologics, Inc. FBLG
medium
Buy
40,000 shares
$13,056
Significance 6/10

General Counsel Ruben Garcia buys 40,000 shares of FBLG at $0.33; stock at -69.6% from 52-week high; cluster buy pattern detected.

Ruben Garcia, General Counsel, purchased 40,000 shares at $0.33 on 2026-02-27, increasing his holdings by 28.6% to 180,000 shares total. The transaction occurred at a significant discount to the 52-week high of $27.60, though the stock has recovered 26.4% over the past 30 days and 59.4% over 90 days from depressed levels. Notably, 2 other insiders bought FBLG within the past 14 days, forming a cluster buy pattern that suggests coordinated or corroborating conviction at these price levels. The company reported negative net income of $-5.8M in its most recent fiscal year, so this buy occurs in a fundamentally unprofitable context where price momentum rather than earnings improvement appears to be driving the recent recovery.

December 2025
2025-12-12 FibroBiologics, Inc. FBLG
high
Buy
140,000 shares
$47,600
Significance 6/10

General Counsel Ruben Garcia buys 140,000 shares of FBLG at $0.34 in initial purchase; stock trades -83.7% from 52-week high at $7.86

FBLG General Counsel Ruben Garcia purchased 140,000 shares at $0.34 per share for a total of $47,600.00, representing his first disclosed holdings in the company. The transaction occurs as FBLG trades at $7.86, down 83.7% from its 52-week high of $48.20, and the company reported a full-year net income of $-5,778,000.00, indicating ongoing unprofitability. The entry at a deeply depressed price relative to recent trading history and the executive's new full-position initiation merit investor attention to whether this reflects management confidence in a turnaround strategy or other motivations, particularly given the company's negative earnings backdrop.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access